International and domestic tax issues. Implementation of PL 119-21.
2026 · 3rd Quarter (July 1 - Sep 30)
ELI LILLY & COMPANY
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- ELI LILLY & COMPANY
- Filing UUID
- a1045060-72de-45fa-9151-42967b56af1d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794). FDA actions on drug compounding and illicit drugs. Issues related to TrumpRX. Alzheimer's Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267).
Literal federal measure citations: HR6509, S3794, H.R. 6130, S. 3267
Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to most favored nation pricing polices.
Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.
Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights. Issues related to China WRT the BINSA bill.
Issues related to pharmaceutical manufacturing and development. Issues related to China WRT the BINSA bill.
Drug importation, prescription drug safety, value and access.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.